The Resound Vivia 9 60S microRIE is a premium prescription behind-the-ear hearing aid released in 2025, priced at $3,798. In our lab testing, it earned a B grade with a SoundScore of 3.94/5, ranking #20 of 35 devices in the Prescription Hearing Aid category.
This device demonstrates particular strength in speech clarity during quiet listening situations, scoring 4.0/5—a strong result that sits +0.57 points above the category average. Own-voice comfort also performs well at 3.4/5, measuring +0.67 points above average, which should translate to a more natural sound when speaking. These characteristics make the Vivia 9 well-suited for users who spend significant time in quieter environments like homes, offices, or one-on-one conversations.
Performance in challenging noise situations is more limited, with speech-in-noise scoring 1.3/5—a low absolute score that also falls -0.23 points below category average. Feedback handling scores 4.2/5, which is strong in absolute terms, though it comes in -0.54 points below the category average. Music streaming lands at 2.6/5, essentially matching the category average with mixed overall quality.
At this premium price point, several alternatives in the same range deliver higher overall scores, including the Oticon Intent (4.70/5) and Phonak Sphere Infinio (4.64/5). Buyers prioritizing speech clarity in quiet settings and own-voice comfort may find the Vivia 9 appealing, but those frequently encountering noisy environments should consider alternatives with stronger noise performance.
